Serum tau protein elevation in migraine: a cross-sectional case-control study.

"Declarations Competing interestsLHO has nothing to declare. BR received speaker fees from Abbvie/Allergan, Lilly, Lundbeck, Novartis, Teva, and grant support for research or education form Novartis, the German Migraine and Headache Society (DMKG) and the German Research Foundation (DFG). BR is member of the junior editorial board of The Journal of Headache and Pain, and editorial board of Frontiers in Neurology. RF received speaker fees from Novartis. MS has nothing to declare. AV has nothing to declare AMM has nothing to declare. KR received speaker fees from Bayer, travel grants from Guthy Jackson Charitable Foundation, and grant support for research or education from Novartis Pharma, Merck Serono, German Ministry of Education and Research, European Union (821283–2), Stiftung Charité (BIH Clinical Fellow Program) and Arthur Arnstein Foundation. WS, MK, MA, and ND are current or former employees of Novartis Pharma. AS received speaker fees from Teva and congress fees from Novartis. JK received speaker fees, research support, or travel support from or served on advisory boards for Swiss MS Society, Swiss National Research Foundation (320030_189140/1), University of Basel, Progressive MS Alliance, Bayer, Biogen, Celgene, Merck, Novartis, Roche, and Sanofi. UR received speaker or consulting fees from Amgen, Allergan, Abbvie, Eli Lilly, Lundbeck, Novartis, Medscape, Pfizer, StreaMedUp, and Teva, and received grant support for research or education from Novartis (CHERUB01) and German Federal Ministry of Education and Research. UR is treasurer of the EHF and serves as associate editor of the Journal of Headache and Pain and Frontiers in Neurology. Competing interests LHO has nothing to declare. BR received speaker fees from Abbvie/Allergan, Lilly, Lundbeck, Novartis, Teva, and grant support for research or education form Novartis, the German Migraine and Headache Society (DMKG) and the German Research Foundation (DFG). BR is member of the junior editorial board of The Journal of Headache and Pain, and editorial board of Frontiers in Neurology. RF received speaker fees from Novartis. MS has nothing to declare. AV has nothing to declare AMM has nothing to declare. KR received speaker fees from Bayer, travel grants from Guthy Jackson Charitable Foundation, and grant support for research or education from Novartis Pharma, Merck Serono, German Ministry of Education and Research, European Union (821283–2), Stiftung Charité (BIH Clinical Fellow Program) and Arthur Arnstein Foundation. WS, MK, MA, and ND are current or former employees of Novartis Pharma. AS received speaker fees from Teva and congress fees from Novartis. JK received speaker fees, research support, or travel support from or served on advisory boards for Swiss MS Society, Swiss National Research Foundation (320030_189140/1), University of Basel, Progressive MS Alliance, Bayer, Biogen, Celgene, Merck, Novartis, Roche, and Sanofi. UR received speaker or consulting fees from Amgen, Allergan, Abbvie, Eli Lilly, Lundbeck, Novartis, Medscape, Pfizer, StreaMedUp, and Teva, and received grant support for research or education from Novartis (CHERUB01) and German Federal Ministry of Education and Research. UR is treasurer of the EHF and serves as associate editor of the Journal of Headache and Pain and Frontiers in Neurology."

"Funding Open Access funding enabled and organized by Projekt DEAL. This study was supported by a Novartis AG (Switzerland) research grant to UR."